Saddle up for better dividend options
The so-called Magnificent Seven dividend payers might not be completely unavoidable, but investors should saddle up to find attractive alternatives.
The so-called Magnificent Seven dividend payers might not be completely unavoidable, but investors should saddle up to find attractive alternatives.
Alterity Therapeutics reports positive topline results from open-label phase II clinical trial of lead drug ATH434 in multiple system atrophy.
Norfolk Metals has raised $3.5 million in a placement to fund its maiden drilling of the Carmen copper project in Chile.
Here’s everything you need to know before the ASX opens today.
Good morning! Here’s everything you need to know before the ASX flings open its doors and begins trading today.
With 52 per cent of Australian crypto investors reporting a profit in 2025, tax time is top of mind. Binance answers common crypto tax questions.
Former RHC Australia CEO and EMVision’s newest board director Carmel Monaghan believes the company’s early stroke-detection tech has huge potential.
The ASX has fallen 0.31pc with 10 of 11 sectors lower. Healthcare lifted 1.04pc, posting solid gains despite market riptides.
GT1 has defined a maiden rubidium resource that enhances its large lithium resource and adds a new dimension to Seymour value calculations.
February saw Trump’s tariffs shake up the markets, with ASX tech taking a hit, led by WiseTech’s sharp drop.
The IoT boom is transforming industries, with Simble, EP&T, and X2M Connect leading the ASX in this space.
As China and the European Union engage in their 25th high-level summit in Beijing late this week, a delicate dance is unfolding.
Original URL: https://www.couriermail.com.au/business/stockhead/page/10